⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Sikander Ailawadhi Zi Chen Bo Huang Aneel Paulus Mary C. Collins Lei Fu Mingyu Li Mohammad Ahmad Lichuang Men Hengbang Wang Matthew S. Davids Eric Liang Divya J. Mekala Zhicong He Masa Lasica Costas K. Yannakou Ricardo Parrondo Laura Glass Dajun Yang Asher Chanan‐Khan Yifan Zhai

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Summary of BH3 profiling for PBMC samples collected at baseline.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ailawadhi et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522f22 https://doi.org/10.1158/1078-0432.27030976.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial2024
2Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial2024
3Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial2024
4Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial2024
5Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial2024

Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial2024
Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)2025
A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress.2026